Allianz Asset Management »

Rapport Therapeutics shares owned by Allianz Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Allianz Asset Management from 13F filings

Historical chart of Allianz Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Allianz Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Allianz Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $401k 13k 30.34

More positions owned by Allianz Asset Management

Ishares Tr Core S&p500 Etf (IVV)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)
Amazon (AMZN)
Venture Global Com Cl A (VG)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl C (GOOG)
Broadcom (AVGO)
Johnson & Johnson (JNJ)
JPMorgan Chase & Co. (JPM)
Ishares Tr Russell 2000 Etf (IWM)
Mastercard Incorporated Cl A (MA)

View all positions for Allianz Asset Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
BlackRock
Sofinnova Ventures
Vanguard Group
Johnson & Johnson
Baker Bros. Advisors
Vestal Point Capital
Polar Capital Holdings
Trv Gp Vi
Ubs Global Asset Management Americas

View all funds holding Rapport Therapeutics